Distinct roles of MK2 and MK5 in cAMP/PKA- and stress/p38MAPK-induced heat shock protein 27 phosphorylation

Journal of Molecular Signaling

Volumn 6, Issue , 2011, Pages

  Shiryaev, Alexey ^a   Dumitriu, Gianina ^a   Moens, Ugo ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

EID: 79955923760     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-6-4     Document Type: Article

References (33)

1. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912. 10.1126/science.1072682, 12471242.
2. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344. 10.1128/MMBR.68.2.320-344.2004, 419926, 15187187.
3. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008, 9:747-758. 10.1038/nrm2509, 18813292.
4. Arthur JS. MSK activation and physiological roles. Front Biosci 2008, 13:5866-5879.
5. Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci 2008, 13:5359-5373.
6. Gaestel M. MAPKAP kinases - MKs - two's company, three's a crowd. Nat Rev Mol Cell Biol 2006, 7:120-130. 10.1038/nrm1834, 16421520.
7. Shiryaev A, Moens U. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: menage a trois or menage a quatre?. Cell Signal 2010, 22:1185-1192. 10.1016/j.cellsig.2010.03.002, 20227494.
8. Vermeulen P, Berghe WV, Beck IM, De Bosscher K, Haegeman G. The versatile role of MSKs in transcriptional regulation. Trends Biochem Sci 2009, 34:311-318. 10.1016/j.tibs.2009.02.007, 19464896.
9. Perander M, Keyse SM, Seternes OM. Does MK5 reconcile classical and atypical MAP kinases?. Front Biosci 2008, 13:4617-4624.
10. Ronkina N, Kotlyarov A, Gaestel M. MK2 and MK3--a pair of isoenzymes?. Front Biosci 2008, 13:5511-5521.
11. Shi Y, Kotlyarov A, Laabeta K, Gruber AD, Butt E, Marcus K, Meyer HE, Friedrich A, Volk HD, Gaestel M. Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination. Mol Cell Biol 2003, 23:7732-7741. 10.1128/MCB.23.21.7732-7741.2003, 207624, 14560018.
12. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, Dong MQ, Frangou CG, Yates JR, Wright PE, Han J. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007, 128:295-308. 10.1016/j.cell.2006.11.050, 17254968.
13. Schumacher S, Laass K, Kant S, Shi Y, Visel A, Gruber AD, Kotlyarov A, Gaestel M. Scaffolding by ERK3 regulates MK5 in development. Embo J 2004, 23:4770-4779. 10.1038/sj.emboj.7600467, 535084, 15538386.
14. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci 2009, 66:3289-3307. 10.1007/s00018-009-0086-3, 19593530.
15. Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem 2000, 275:38973-38980. 10.1074/jbc.M002856200, 10978313.
16. Kotlyarov A, Yannoni Y, Fritz S, Laass K, Telliez JB, Pitman D, Lin LL, Gaestel M. Distinct cellular functions of MK2. Mol Cell Biol 2002, 22:4827-4835. 10.1128/MCB.22.13.4827-4835.2002, 133920, 12052889.
17. White A, Pargellis CA, Studts JM, Werneburg BG, Farmer BT. Molecular basis of MAPK-activated protein kinase 2:p38 assembly. Proc Natl Acad Sci USA 2007, 104:6353-6358. 10.1073/pnas.0701679104, 1851067, 17395714.
18. Jones SW, Brockbank SM, Clements KM, Le Good N, Campbell D, Read SJ, Needham MR, Newham P. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology. Osteoarthritis Cartilage 2009, 17:124-131. 10.1016/j.joca.2008.05.001, 18562219.
19. Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006, 25:2987-2998. 10.1038/sj.onc.1209337, 16407830.
20. Lopes LB, Flynn C, Komalavilas P, Panitch A, Brophy CM, Seal BL. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. Biochem Biophys Res Commun 2009, 382:535-539. 10.1016/j.bbrc.2009.03.056, 2745729, 19289101.
21. Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007, 50:2647-2654. 10.1021/jm0611004, 17480064.
22. Davis T, Bagley MC, Dix MC, Murziani PG, Rokicki MJ, Widdowson CS, Zayed JM, Bachler MA, Kipling D. Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett 2007, 17:6832-6835. 10.1016/j.bmcl.2007.10.036, 17964780.
23. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, Bavendiek U. Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ Res 2007, 101:1104-1112. 10.1161/CIRCRESAHA.107.156075, 17885219.
24. Gerits N, Mikalsen T, Kostenko S, Shiryaev A, Johannessen M, Moens U. Modulation of F-actin rearrangement by the cyclic AMP/cAMP-dependent protein kinase (PKA) pathway is mediated by MAPK-activated protein kinase 5 and requires PKA-induced nuclear export of MK5. J Biol Chem 2007, 282:37232-37243. 10.1074/jbc.M704873200, 17947239.
25. Kostenko S, Shiryaev A, Gerits N, Dumitriu G, Klenow H, Johannessen M, Moens U. Serine residue 115 of MAPK-activated protein kinase MK5 is crucial for its PKA-regulated nuclear export and biological function. Cell Mol Life Sci 2010,
26. Stokoe D, Engel K, Campbell DG, Cohen P, Gaestel M. Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett 1992, 313:307-313. 10.1016/0014-5793(92)81216-9, 1332886.
27. Zakowski V, Keramas G, Kilian K, Rapp UR, Ludwig S. Mitogen-activated 3p kinase is active in the nucleus. Exp Cell Res 2004, 299:101-109. 10.1016/j.yexcr.2004.05.027, 15302577.
28. Tak H, Jang E, Kim SB, Park J, Suk J, Yoon YS, Ahn JK, Lee JH, Joe CO. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. Cell Signal 2007, 19:2379-2387. 10.1016/j.cellsig.2007.07.016, 17728103.
29. Kostenko S, Johannessen M, Moens U. PKA-induced F-actin rearrangement requires phosphorylation of Hsp27 by the MAPKAP kinase MK5. Cell Signal 2009, 21:712-718. 10.1016/j.cellsig.2009.01.009, 19166925.
30. New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, Kato Y, Parry GC, Han J. PRAK, a novel protein kinase regulated by the p38 MAP kinase. Embo J 1998, 17:3372-3384. 10.1093/emboj/17.12.3372, 1170675, 9628874.
31. Seternes OM, Johansen B, Hegge B, Johannessen M, Keyse SM, Moens U. Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress. Mol Cell Biol 2002, 22:6931-6945. 10.1128/MCB.22.20.6931-6945.2002, 139805, 12242275.
32. Howe AK. Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta 2004, 1692:159-174. 10.1016/j.bbamcr.2004.03.005, 15246685.
33. Debbas V, Arai RJ, Ferderbar S, Schindler F, Stern A, Moneiro HP. Regulation of p21Waf1 expression and TNFa biosynthesis by glutathione modulators in PMA induced-THP1 differentiation: Involvement of JNK and ERK pathways. Biochem Biophys Res Comm 2007, 363:965-970. 10.1016/j.bbrc.2007.09.091, 17920036.